Radiopharmaceuticals are used to produce images of organs or tissues of interest, a process that is called scintigraphy. While, contrast media is used in imaging techniques to enhance the differences between body tissues on images. It is a substance used to increase the contrast of structures/fluids within the body in medical imaging.
Market Dynamics:
Increase in prevalence of cardiovascular diseases, rise in burden of cancer, increasing number of diagnostic centres, increasing demand for image-guided procedures and diagnostics, and increase in demand for diagnostic radiopharmaceuticals and contrast media, are major factors expected to propel growth of the global diagnostic radiopharmaceuticals and contrast media market.
For instance, in October 2022, Duchem Bio announced the launched of FACBC, the world’s first radiopharmaceutical used when diagnosing prostate cancer patients, in Korea. The drug, developed by Nihon Medi Physics, a Japanese pharmaceutical company, is used when conducting positron emission tomography (PET) in patients suspected of having prostate cancer recurrence due to an increase in the prostate-specific antigen (PSA) in the blood after prostate cancer treatment.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook